Trial reportThe Journal of clinical endocrinology and metabolism2015
Bone Density After Teriparatide Discontinuation in Premenopausal Idiopathic Osteoporosis.
Trial report in The Journal of clinical endocrinology and metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03396315 (Bisphosphonates for Prevention of Post-Denosumab Bone Loss in Premenopausal Women With Idiopathic Osteoporosis), which is not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Bisphosphonates for Prevention of Post-Denosumab Bone Loss in Premenopausal Women With Idiopathic Osteoporosis
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Pharmacological interventions to improve bone density in functional hypothalamic amenorrhea: a systematic review and network meta-analysis of randomized clinical trials.The Journal of clinical endocrinology and metabolism · 2026Pooled it
- Spine Volumetric BMD and Strength in Premenopausal Idiopathic Osteoporosis: Effect of Teriparatide Followed by Denosumab.The Journal of clinical endocrinology and metabolism · 2022Trial
- Denosumab After Teriparatide in Premenopausal Women With Idiopathic Osteoporosis.The Journal of clinical endocrinology and metabolism · 2022Trial
- Four-Year Teriparatide Followed by DenosumabFrontiers in endocrinology · 2021Trial
- Effect of Teriparatide on Bone Remodeling and Density in Premenopausal Idiopathic Osteoporosis: A Phase II Trial.The Journal of clinical endocrinology and metabolism · 2020Trial
- Open-label clinical trial of alendronate after teriparatide therapy in people with spinal cord injury and low bone mineral density.Spinal cord · 2019Trial
- Bisphosphonates Maintain BMD After Sequential Teriparatide and Denosumab in Premenopausal Women with Idiopathic Osteoporosis.The Journal of clinical endocrinology and metabolism · 2025Article
- Multiple thoracolumbar compression fractures induced by glucocorticoid-induced osteoporosis and cachexia in a young adult female patient with systemic lupus erythematosus: a case report with a 5-year follow-up.Oxford medical case reports · 2024Article
- Advancement in the Treatment of Osteoporosis and the Effects on Bone Healing.Journal of clinical medicine · 2022Review
- Distinct Responses of Modeling- and Remodeling-Based Bone Formation to the Discontinuation of Intermittent Parathyroid Hormone Treatment in Ovariectomized Rats.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022Article
- Short Cyclic Regimen With Parathyroid Hormone (PTH) Results in Prolonged Anabolic Effect Relative to Continuous Treatment Followed by Discontinuation in Ovariectomized Rats.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022Article
- Dilemmas in the Management of Osteoporosis in Younger Adults.JBMR plus · 2022Review
- Bone Density After Teriparatide Discontinuation With or Without Antiresorptive Therapy in Pregnancy- and Lactation-Associated Osteoporosis.Calcified tissue international · 2021Article
- Review of Current Real-World Experience with Teriparatide as Treatment of Osteoporosis in Different Patient Groups.Journal of clinical medicine · 2021Review
- Spinal Cord Injury as a Model of Bone-Muscle Interactions: Therapeutic Implications FromFrontiers in endocrinology · 2020Review
- Article
- Updates in CKD-Associated Osteoporosis.Current osteoporosis reports · 2018Review
- Parathyroid hormone regulates fates of murine osteoblast precursors in vivo.The Journal of clinical investigation · 2017Article
- Premenopausal Osteoporosis.Endocrinology and metabolism clinics of North America · 2017Review
- Assessment and clinical management of bone disease in adults with eating disorders: a review.Journal of eating disorders · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
contextWithout antiresorptive therapy, postmenopausal women lose bone mass after teriparatide (TPTD) discontinuation; estrogen treatment prevents bone loss in this setting. It is not known whether premenopausal women with regular menses lose bone mass after teriparatide discontinuation.
objectiveThis study aimed to test the hypothesis that normally menstruating premenopausal women with idiopathic osteoporosis (IOP) will maintain teriparatide-associated bone mineral density (BMD) gains after medication cessation.
designTwenty-one premenopausal IOP women previously enrolled in an open-label pilot study of teriparatide (20 mcg for 18-24 mo), had substantial BMD increases at the lumbar spine (LS; 10.8 ± 8.3%), total hip (TH; 6.2 ± 5.6%), and femoral neck (7.6 ± 3.4%). For this study, BMD was remeasured 2.0 ± 0.6 years after teriparatide cessation.
participantsFifteen women, who had gained 11.1 ± 7.2% at LS and 6.1 ± 6.5% at TH and were premenopausal at teriparatide completion, were followed without antiresorptive treatment.
resultsTwo years after completing teriparatide, BMD declined by 4.8 ± 4.3% (P = .0007) at the LS. In contrast, BMD remained stable at the femoral neck (-1.5 ± 4.2%) and TH (-1.1 ± 3.7%). Those who sustained LS bone loss >3% (-7.3 ± 2.9%; n = 10), did not differ from those with stable LS BMD (0.1 ± 1.1%; n=5) with regard to baseline body mass index, BMD at any site, or duration of followup, but were significantly older at re-evaluation (46 ± 3 vs 38 ± 7; P = .046), had larger increases in LS BMD during teriparatide treatment and higher cancellous bone remodeling on transiliac biopsy at baseline and completion of teriparatide treatment. Serum bone turnover markers did not differ at baseline or teriparatide completion, but tended to be higher at the re-evaluation timepoint in those with post-teriparatide bone loss.
conclusionsThese findings lead us to conclude that premenopausal women with IOP, particularly those over 40, may require antiresorptive treatment to prevent bone loss after teriparatide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.